NCT01054339View on ClinicalTrials.gov

Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2015

Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
DRUG

rAAV1-CB-hAAT

Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin

Trial Locations (4)

2

Beaumont Hospital, Dublin

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

80206

National Jewish Health, Denver

01655

University of Massachusetts Medical Center, Worcester

Sponsors
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Beacon Therapeutics

INDUSTRY